Results 271 to 280 of about 69,426 (314)

Managing Delayed or Missed Doses of Prolonged‐Release Tacrolimus in Transplant Recipients: Implications for Drug Exposure and Recovery Strategies

Basic &Clinical Pharmacology &Toxicology, Volume 138, Issue 1, January 2026.
This simulation–based analysis quantified the impact of delayed and missed doses of prolonged–release tacrolimus in kidney and liver transplant recipients. A single missed dose reduced AUC24h by up to 50% and required 2–4 days to return to steady state.
S. Arraki Zava, F. Maizaud, H. Sayadi, Y. Fromage, P. Marquet, J. B. Woillard, C. Monchaud   +6 more
wiley   +1 more source

From a pyramid to an amphitheatre (triangle to circle): embracing the totality of evidence for the postmarketing evaluation of the safety of therapeutic interventions. [PDF]

BMJ Open
Shakir S, Lane S.
europepmc   +1 more source

When Is It Safe to Introduce an AI System Into Healthcare? A Practical Decision Algorithm for the Ethical Implementation of Black‐Box AI in Medicine

Bioethics, Volume 40, Issue 1, Page 61-72, January 2026.
ABSTRACT There is mounting global interest in the revolutionary potential of AI tools. However, its use in healthcare carries certain risks. Some argue that opaque (‘black box’) AI systems in particular undermine patients' informed consent. While interpretable models offer an alternative, this approach may be impossible with generative AI and large ...
Jemima Winifred Allen, Dominic Wilkinson, Julian Savulescu   +2 more
wiley   +1 more source

Systematic Review and Meta-Analysis of the Incidence of Myocarditis and Guillain-Barré Syndrome in Adolescents Receiving COVID-19 mRNA Vaccine. [PDF]

Cureus
Kumar C, Akhileshwar, Kumar Neeraj R, Hameed S, Husain N, Roy SS, Mohan L, Anantsaznam.   +7 more
europepmc   +1 more source

A Review Harnessing Artificial Intelligence for Enhanced Pharmacovigilance

Ch.Naga Sowjana, Dr.D Rama Bramha Reddy, M.Manisha
openalex   +1 more source

The eyes of the beholder: Perceived barriers to successful drug repurposing

British Journal of Pharmacology, Volume 183, Issue 2, Page 219-233, January 2026.
Despite tremendous advances in new drug development over recent decades, the medical needs of an ever increasing and ageing global population are still significantly unmet. Drug repurposing (DR)—finding new therapeutic uses for existing medicinal substances and products—offers a promising strategy by potentially reducing development time, costs and ...
Zsuzsanna Ida Petykó, Dalma Hosszú, Marcell Csanádi, Kristóf Gyöngyösi, George Dennis Obeng, David Ameyaw, Tamás István Dóczi, Zoltán Kaló, Donald C. Lo, Helene G. van der Meer, Pan Pantziarka, András Inotai   +11 more
wiley   +1 more source

Risk assessment for vaccination programmes in a pandemic. A Swedish model for efficacy and safety during COVID-19. [PDF]

Ups J Med Sci
Wikstöm G, Welsh M.
europepmc   +1 more source

Safety, Tolerability, and Pharmacokinetics of Single Doses of ABBV‐916, an Anti‐Amyloid Antibody, in Healthy Participants

Clinical and Translational Science, Volume 19, Issue 1, January 2026.
ABSTRACT Amyloid‐beta (Aβ) plaque brain clearance is one of the promising disease‐modifying treatment approaches to slow cognitive decline in Alzheimer's disease (AD). ABBV‐916, an anti‐amyloid antibody, was being developed as an early AD disease‐modifying treatment.
Sagar S. Bachhav, Hana Florian, Joey Boiser, Yamin Wang, Dee‐Dee Shiller, Ulrike Graab, Shau Yu Lynch, Ole Graff, Hao Xiong   +8 more
wiley   +1 more source

Editorial: Enhancing therapeutic strategies: a focus on pharmacovigilance in new wave antidepressants and antipsychotics. [PDF]

Front Psychiatry
Vasiliu O, Manchia M, Noguchi Y, Mikellides G.   +3 more
europepmc   +1 more source

Global safety profile of PD-1/PD-L1 inhibitors in hepatic autoimmune disorders: A global disproportionality analysis. [PDF]

Medicine (Baltimore)
Oh J, Kong J, Hwang J, Kim TH, Park J, Cho J, Kim TH, Yon DK.   +7 more
europepmc   +1 more source